A Randomized, Double-Blind, Sponsor Open, Placebo-Controlled, 52 Week
Research payments
$327,704
Through program year 2020, $327,704 in research payments was reported against A Randomized, Double-Blind, Sponsor Open, Placebo-Controlled, 52 Week, across 42 payments, paid by GlaxoSmithKline, LLC..
- Paid by
- GlaxoSmithKline, LLC.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
2 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2020 | Research | $19,435 | 1 |
| 2019 | Research | $308,269 | 41 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Njira Lugogo Northville, MI Named on 8 payments
- Frank Sciurba Pittsburgh, PA Named on 5 payments
- Russell Bowler Denver, CO Named on 4 payments
- Robert Wise Baltimore, MD Named on 4 payments
- Charlene McEvoy Hudson, WI Named on 4 payments
- Janine Vintch Torrance, CA Named on 3 payments
- Nicola Hanania Houston, TX Named on 3 payments
- Gerard Criner Philadelphia, PA Named on 3 payments
- Douglas Conrad San Diego, CA Named on 2 payments
- Mark Dransfield Birmingham, AL Named on 2 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.